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ABBREVIATIONS 
uSpA  Undifferentiat ed Spondyloarthrop athy  
SpA  Spondy loart hropathy  
AS  Anky los ing Spondylit is  
PsA  Psoriat ic Arthrit is  
IBD  Inflammatory Bowel Disease 
RA  Rheumatoid Arthrit is  
ER  Endop lasmic Ret iculum 
TAP  Transport er associat ed with Ant igen Process ing 
PLC  Peptide Loading Complex 
ERAP1  Endop lasmic Reticulum Aminopeptidase associated with 
ant igen process ing 
ART S1  Aminopeptidase Regulator of TNF receptor Shedding 
ERAD  ER Associat ed Degradat ion 
UPR  Unfolded Prot ein Response 
ATF6  Act ivat ing Transcription Factor 
IRE1  Inos itol Requiring Enzy me  
PERK  RNA act ivat ed Protein kinase(PKR) like ER Kinase  
XBP  X box Binding Protein 
BiP  Binding Immunoglobulin Prot ein 
NFκB  Nuclear Factor kappa light  chain enhancer of activated B cells  
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KIR  Killer cell Immunoglobulin like Receptors  
ILT   Immunoglobulin Like Transcripts 
MICA/MICB  MHC class  I Chain relat ed genes A and B 
CARD  Caspase Recruit ment  Domain 
LMP  Low Molecular weight Pept ide 
RFT  Renal Funct ion T est  
LFT  Liver Funct ion T est  
RF  Rheumatoid Factor 
CRP  C React ive Protein 
ASO  Anti Streptolysin O 
HLA  Human Leukocyte Antigen 
BASDAI  Bat h Anky los ing Spondylit is Disease Activity Index 
BASFI  Bat h Anky los ing Spondylit is Funct ional Index 
BASMI  Bat h Anky los ing Spondylit is Met rology Index 
HAQ  Health Assessment  Quest ionnaire 
TGF Transforming Growth Fact or   
 
 
77
INDEX 
S.NO  CONTENT PAGE NO. 
1.  INTRODUCTION 1 
2.  AIMS AND OBJECTIVES 2 
3.  REVIEW OF LIT ERATURE 3 
4.  MATERIALS AND METHODS 37 
5.  RESULT S OF THE DATA 41 
6.  DISCUSSION 58 
7.  CONCLUSION 63 
8.  BIBLIOGRAPHY  
9.  ANNEXURE 
A) PROFORMA 
B) MASTER CHART 
C) PAT IENT CONSENT FORM 
D) ETHICAL COMMITTEE APPROVAL ORDER 
   
 1 
INTRODUCTION 
Undifferentiat ed spondyloart hropathy is  a syndrome wit h feat ures 
cons ist ent  with the spondy loarthropat hies  but  affected pat ients  do not fulfill 
crit eria for any specific spondyloarthrop athy.1 
Undifferentiat ed spondy loart hropathy  may represent  an early phase or 
incomp lete form of ankylos ing spondy litis  or anot her spondyloarthropat hy. 
No large scale multinational studies  have report ed on t he signs and 
sy mptoms of  undifferent iated spondyloarthropat hy. Because it  is defined by 
the exclus ion of t radit ionally  well recogniz ed arthritides, p at ients  determined 
to have undifferent iat ed spondyloarthrop athy probably  exhibit a mixture of 
diverse signs  and symptoms, one of which is  eit her inflammat ory  low back 
ache or asymmetric oligoarthritis .1  
No large scale longitudinal st udies  are available concerning the course 
and prognos is  of  undifferent iat ed spondy loart hropathy. Some studies  show 
that  aft er several years  of follow up, some pat ients  go into remiss ion, some 
develop ankylos ing spondylit is,  and ot hers  continue to have undifferentiat ed 
spondy loart hropathy. A cons iderable number of p atients were initially 
misdiagnosed wit h spondyloart hropathy, and t heir actual diagnoses , such as 
rheumatoid art hrit is  (RA) or gout , did not  become clear until several y ears 
lat er.  Clearly, a diagnost ic method based on somet hing other than exp ert 
op inion or class ification crit eria is  needed. M ost  useful would be p aramet ers 
that  can predict whether a p atient will progress  rap idly int o AS, because these 
pat ients  might  benefit from early aggress ive therapy.1  
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AIMS AND OBJECTIVES 
1) To study the clinical profile of undifferentiat ed spondyloart hropathy. 
2) To assess  the out come of undifferent iated spondyloart hropathy  aft er 
one y ear of follow up. 
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REVIEW OF LITERATURE 
The spondyloart hropathies  are a family of relat ed disorders t hat 
includes  ankylos ing spondy litis ,  psoriat ic art hrit is,  reactive art hrit is, 
art hropathy  of inflammat ory bowel disease, juvenile ankylosing spondy lit is 
and undifferent iated spondyloarthropat hy.5  
Undifferentiat ed spondyloart hropathy is  a syndrome wit h feat ures 
cons ist ent  with the spondy loarthropat hies  but  affected pat ients  do not fulfill 
crit eria for any specific spondyloarthrop athy.1  
CLINICAL CHARACTERISTICS OF 
SPONDYLOARTHROPTHIES5  
1) Typical patt ern of p eripheral art hrit is- predominant ly of lower limb, 
asymmetric. 
2) T endency towards  radiographic sacroiliit is.  
3) Absence of rheumatoid factor. 
4) Absence of subcutaneous nodules  and other extra articular features of     
rheumatoid art hrit is.  
5) Overlapping extra art icular features  charact erist ic of t he group 
(eg:ant erior uveit is) 
6) Significant  familial aggregat ion  
7) Associat ion with HLA -B27. 
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EPIDEMIOLOGY OF SPONDYLOARTHROPATHY  
Indian dat a on t he epidemiology  of spondyloarthropat hy are scarce. 
Prevalence dat a from the first  Indian COPCORD (Community Orient ed 
Program from Cont rol of Rheumat ic Diseases) survey  showed the rural 
prevalence of back ache t o be 17.3%. T his  included bot h inflammatory and 
mechanical back aches.4 Of all the peop le wit h low back ache, about  1-2% are 
likely  to have SpA. From this  rural cohort,  the SpA prevalence can be 
est imat ed at about  0.17-0.34%. 
Dat a from a large clinic in North India (over 800 pat ients  of rheumatic 
diseases  on follow up) suggests  t hat  the rat io of rheumatoid arthritis  (RA) to 
ankylos ing spondylit is  (AS) is  about  3.2:1. Since the prevalence of RA in 
India is about  0.7%, that of AS is likely to be 0.2%. 
 T he prevalence of AS in a populat ion is direct ly relat ed to the 
frequency of HLA B27 ant igen in the community.5 The frequency  of HLA 
B27 in the North Indian population is  6%, s imilar to that in Caucas ians .    The 
prevalence of AS in Caucas ians  is  0-1%. Hence the prevalence in India is 
likely t o be s imilar. Hence, by these three ways  of reasoning, we could 
est imat e t he prevalence of SpA in India to be between 0.1 to 0.2%. 
Prevalence dat a for uSpA are scarce, although t his  disorder appears  to 
be at  least  as  common as  AS, if not  more so. Its  actual prevalence may  be as 
high as 1-2% of t he general populat ion. 
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The male/female ratio is  about  2/1 to 3/2 wit h an age of onset  ranging 
from 16-70 y ears . Family  history is  p os itive in around 14% in 
undifferent iat ed spondy loart hropathy.30  
PATHOGENESIS 
The precise cause of spondy loart hropathy is  unclear. There is a major 
genet ic contribut ion. HLA B27 is  directly  involved in the p athogenes is  of 
disease and addit ional non MHC genes  cont ribut e t o t he p athogenes is. 
Cartilage appears  to be the primary t arget  t issue for the abnormal immune 
response. Cytokine dysregulat ion with overexp ress ion of TNFα and intest inal 
inflammat ion are prominent features  of disease. Bone morphogenet ic prot eins 
(BMP) p lay a role in the p athogenes is  of anky los is .5  
GENETIC FACTORS 
The dominant  role of genet ic factors  is  highlight ed by data 
demonst rat ing disease concordance in 75% of monozy got ic twins  compared 
with 13% of non ident ical twins, familial aggregat ion and association with 
HLA B27.5  
HLA B27 
HLA B27 contribut es  only 16% of t he t otal genetic risk. Forty  five 
subtypes  have been ass igned on the bas is  of nucleot ide sequence homology 
that  encodes  more than 20 different  products.5 The most common subtype 
seen worldwide is  B*2705, followed by B*2702. B*2706 is  t he most common 
subtype seen in Asians but  it is  neut ral or weakly associat ed with disease. 
B*2709 is not  associat ed with axial disease, although peripheral art hrit is  have 
been report ed.6  
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The HLA B27 subtypes  commonly seen in south india were HLA 
B*2704 and HLA B*2705. The prevalence of HLA B27 in India – in 
T amilnadu 4.1% and in North India 6%.7  
The main function of HLA B27 is t o present peptides t o CD8 T cells. 
Crystallographic analys is  of B*2705 shows a pept ide binding groove with 
pockets  (A to F). The B pocket  is  conserved among B27 subtypes. It  has  a 
glutamine amino acid at  pos it ion 45 t hat  int eracts  wit h arginine at  p os ition 2 
of B27 bound peptides. This pocket conveys sp ecificity for the type of p eptide 
bound to B27.5  
ARTHRITOGENIC PEPTIDE HYPOTHESIS 
It  has  been proposed that t he ant igen presenting prop ert ies  of HLA B27 
could be crucial in the pathogenesis of spondyloarthrop athy. 
Molecular Mimicry 
Molecular mimicry  is  defined as  the sharing of ep itopes  from disparate 
prot eins. Although their origins  may be as  different as  a microbe and a normal 
host  prot ein, the linear amino acid sequences or the conformat ional fits of two 
such molecules  may be homologous. An immune response, init iat ed by an 
invading microbe, i.e. , bact erium, virus , or paras ite, may then react  not only 
with that  microbe, but also wit h t he homologous host protein. Conceptually, 
molecular mimicry  can occur whenever the microbial and host  determinants 
are sufficient ly similar t o induce a cross  react ing immune response, yet 
different enough to break immunologic self t olerance.10  
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This  hypothes is  suggests  that  because of their unique aminoacid 
res idues , some B27 subtypes  bind sp ecific art hritogenic bact erial p eptides 
that  are recognised by  CD8 T  cells .  In response to t hese bact erial peptides, 
aut oreactive T  cell recogniz ing ant igens  wit h sufficient  structural s imilarity 
between bact eria and self might become activated by self pept ides  such as 
those in joints and sp ine.8 This  process  is  supported by  int egrins , which are 
relevant for the homing of cross react ive CD8 T  cells  into the joint.  
One major support  for this  hypothes is  came from studies showing the 
different ial association of natural HLA B27 subtypes  t o spondyloart hropathy. 
While B*2705, B*2702, B*2704 and B*2707 are strongly  associated with 
disease, the subtypes  B*2709 in Caucas ians  and B*2706 in As ians  are not  at 
all or only  rarely  present  in spondyloarthrop athy  pat ients .  T hese two 
subtypes  differ from t he disease associat ed ones  only  by  one aminoacid 
subst itut ion (B*2705 to B*2709)  by exchange of  an Asp116 t o His116,  or two 
aminoacid subst itut ions  (B*2704 to B*2706) by  exchange of His114 t o Asp114 
and of Asp116 to Tyr116,  all of which are locat ed in t he p eptide binding 
groove.9 It  has  therefore been hypothes iz ed that  B*2706 and B*2709 subtypes 
do not  present  arthrit ogenic p eptides  in contrast  with t he disease associat ed 
ones. 
This  t heory has  been supported by animal st udies  also. B27 transgenic 
rats  do not  develop art hrit is if maint ained in a germ free environment. 
Exposure of t hese rats  t o bact eria, esp ecially bacteroides  species, t riggers  the 
onset of both int estinal and joint inflammat ion. 
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MOLECULAR MIMICRY BETWEEN HLA B27 AND 
BACTERIA  
HLA B27 can also act  as an autoant igen. Studies have shown t here is 
molecular mimicry between the amino acid res idues  72-77 of HLA B27 and 
188-193 of Klebs iella  pneumoniae nit rogenase reduct ase enzyme 
(QTDRED).10 T he cross  reactivity between t hese ant igens  evokes  immune 
response against  the host .  Experiments  in Lewis  rats  have shown that  the 
same B27 derived p eptide is  cross  recognized wit h a homologous  p eptide 
derived from cytokeratin, a prot ein that is  sp ecifically expressed in synovial 
membranes, gut epit helium and ey es, and t hat  immuniz at ion with either 
peptide induces  art hrit is and uveit is .  
MISFOLDING OF PROTEINS  
To transport  the pept ide t o t he cell surface, HLA class  I heavy chains 
must fold properly, bind β2m and then load peptide prior t o exit ing the 
endop lasmic ret iculum (ER) compart ment. High st ability of t he trimolecular 
complex is  essent ial for efficient  transport t hrough the golgi comp lex. The 
st ability of HLA class I complexes  is critically dependent on early events  in 
the folding and assembly process, including the format ion of two intrachain 
disulfide bonds.11 T he α3 domain folds  very rap idly  and is  st abilized by  an 
int radomain disulfide bond between Cys-203 and Cys-259. The α1 and α2 
domains  fold more s lowly and this  is  not  comp lete unt il peptide is  stably 
bound. A second disulfide bond between the α1 and α2 domains  (Cys-101 and 
Cys-164) maintains  the int egrity of t he p eptide binding groove12 as  the heavy 
chain/β2m het erodimer int eracts  with tap as in, ERp57 and the transport er 
associat ed with antigen process ing (TAP) to form t he p eptide loading 
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complex (PLC). HLA- B27 (the B*2705 subtype) is  expressed relat ively 
efficiently  in tap as in-deficient  cells 13 and is  frequent ly referred to as a 
t apas in-independent  allelle. The ability of HLA-B27 to be expressed at  high 
levels  on t apas in-deficient cells  may reflect its  tendency to fold s lowly and be 
ret ained in t he ER in a p eptide receptive st ate without  tap as in-PLC 
int eract ion.14 T his  could favor t he binding and optimizat ion of available 
peptides wit hout t apas in mediat ed ret ent ion. 
ERp57 binds  to tap as in via a disulfide bond and plays an import ant 
role in disulfide bond isomeriz at ion in t he heavy  chain during class  I 
assembly. Recent  evidence indicates  t hat formation of t he ERp57-tap as in 
conjugat e prevents  ERp57- mediat ed reduct ion of the α1α2 int erdomain 
disulfide in t he class  I heavy  chain, t hus  maintaining t he pept ide binding 
groove in a receptive st at e. When t apas in is miss ing or mut ated at  Cys-95 and 
thus  unable to form a complex with ERp57, the class  I heavy chain α1α2 
disulfide is  reduced until suitable p eptide can bind. Free ERp57 (or ERp57-
calreticulin comp lexes) appears  t o catalyze t his  reduct ion in the absence of 
t apas in leading to the concept that  t apas in performs  its  funct ion by 
sequest ering ERp57. 
The final stages  of p eptide binding t o HLA class  I molecules  includes 
trimming by  t he ER aminopeptidase associat ed wit h ant igen process ing 
(ERAP1).15 In addit ion to peptide trimming for present ation by class  I 
molecules , ERAP1 appears  to have anot her role in the immune syst em. It  was 
discovered indep endent ly as Aminopeptidase Regulat or of TNF Receptor 
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Shedding (ART S-1), but  also regulat es  shedding of IL-6 and IL-1 decoy 
receptors . 
There are molecular chaperone syst ems t hat ass ist  and monitor the 
folding process  to ensure high fidelity  product ion of proteins  that  can 
funct ion prop erly. When prot ein folding does  not  occur properly, due to 
mut at ions  or p olymorphims  that  alt er the aminoacid sequence, or 
abnormalit ies  in components  of the chap erone syst ems, misfolding can result. 
Many  misfolded and even incomp let ely  folded ER prot eins  can be eliminat ed 
efficiently by ER-associat ed degradat ion (ERAD) if they have remained in the 
ER for a sufficient  time. The cellular response t o ER protein mis folding 
referred to as  the UPR (unfolded protein response), is  part of a more global 
homeost at ic response t o ER st ress. 
THE UNFOLDED PROTEIN RESPONSE  
One of the consequences  of prot ein misfolding in t he ER can be 
act ivation of the UPR. T here are three main effect or molecules  of the UPR, 
the ATF6 t ranscript ion fact or and the two kinases IRE1 and PERK. These 
effect or molecules  res ide within t he ER and are maintained in an inact ive 
st ate by t he ER res ident chaperone Immounoglobulin Binding Prot ein (BiP). 
During ER stress , BiP  is  sequest ered away from these effect or 
molecules , leading to their act ivat ion. Dissociat ion from BiP  unmasks 
t arget ing s ignals, which trans locat e ATF6 t o t he golgi apparat us. Within the 
golgi apparat us, p rot eolytic p rocess ing of t he ATF6 cytosolic domain by  two 
res ident  proteases . The ATF6 cytosolic domain is  then trans locat ed to the 
nucleus  and acts  as  a pot ent  transcription factor upregulating chap erones 
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participat ing in prot ein folding. Prolonged ER stress  can induce the 
oligomerisat ion and autophosphorylat ion of the ER res ident IRE1 and PERK 
kinases. Phosphory lat ed IRE1 can sp lice the cytosolically locat ed XBP1 
mRNA. XBP1 can act ivat e chap erones  to enhance cellular folding capacity 
and/or prot eins  involved in the degradation of mis folding substrat es. 
Act ivat ed PERK can phosphory lat e elongat ion factor 2α (eF2α), which 
inhibits  protein synthes is , thus  reducing t he prot ein load wit hin the ER. 
Furt hermore PERK can act ivat e a series  of transcription factors  which can 
lead to the induct ion of apoptos is, t hus  leading t o the removal of t erminally 
distressed cells.  T he ER overload response remains  poorly defined, but  it is  
thought  t hat  accumulation of misfolded prot eins  within the ER leads  t o the 
act ivation of t he transcription factor NFκB. As  NFκB can t arget 
proinflammat ory  cytokine genes , act ivat ion of t his  transcription factor could 
be a key  link between HLA-B27 misfolding and the product ion of 
proinflammat ory cytokines IL-1 and TNFα.16  
Furt hermore, proinflammat ory cytokines, not ably TNFα, can induce 
ER st ress. This  raises  the poss ibility that,  if  HLA-B27 misfolding does induce 
ER stress  and lead to p roinflammat ory  cytokine p roduct ion, t his  could 
develop int o a pos it ive feedback loop which exacerbat es  and p erp etuates the 
release of TNFα and ot her pro-inflammatory  mediators. T hus  t here does 
indeed appear to be a link between ER stress  and a proinflammatory  cytokine 
environment , which is  a characteristic feature of SpA pat ients . 
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HEAVY CHAIN HOMODIMER FORMATION 
An unusual characteristic feat ure of HLA B27 is  its  ability to form 
heavy chain homodimers . This  p rop erty  is  dep endent  on t he rare cysteine 
res idue at  pos ition 67 which can form a disulfide bridge but  cysteine res idues 
at  ot her pos it ions  can also form homo dimers  ( eg: p os it ion 164 ).  B27 is  not 
the only  HLA class  I molecule t hat  can form dimers. HLA A2 can also form 
homodimers. T he prop erty of B27 to form dimers  may  be relat ed to its 
misfolding.19  
KILLER CELL IMMUNOGLOBULIN LIKE RECEPTORS 
HLA B27 homodimers  were recogniz ed by receptors  belonging t o a 
family called killer cell immunoglobulin like receptor (KIR) family. Killer 
cell immunoglobulin like receptors  (KIRs) are expressed on natural killer 
(NK) cells  and some T  cells,  including act ivat ed CD8+  T  cells  that  interact 
with class  I HLA molecules  (including HLA-B27). There are many receptors, 
of which KIR3DL1 and KIR3DS1 are import ant in the pathogenes is of SpA. 
   
 13 
HLA B27 can be recognized by KIR3DL1 conferring a strong inhibit ion and 
preventing lys is  of t he cell.  Recognit ion of B27 by KIR3DL1 can be blocked 
(some viral peptides  may  cause t he blockage of t he inhibitory  receptor 3DL1 
or KIR3DL1 polymorphism can serve to alter the inhibitory  response).17 So, a 
microbial infect ion can cause activation of act ivat ing NK receptors 
(KIR3DS1) and t he subsequent  progress ion to AS.18  
Heavy  chain homodimers  can also bind wit h immunoglobulin like 
transcripts (ILT ) or leukocyte Ig like receptor family. Homodimer binding 
with KIR and ILT has been shown to st imulate the release of TNFα.  
NON B27 HLA GENES 
HLA B60 carries  an increased risk for spondyloart hropathy. 
Associat ions  of B27 negat ive AS have also been report ed with HLA alleles  in 
the B27 cross  reactive group  (B7, B22, B40, B41, B42). An increased risk has 
been associat ed with HLA B39.  
Polymorphism in TNFα has  been associat ed wit h spondyloart hropathy. 
A s ignificant decrease in t he A allele at posit ion 308 has  been found in 
spondy loart hropathy. 
Polymorphisms  in MHC class  I chain relat ed genes  A and B (MICA 
and  MICB) also contribut es  to spondyloarthropat hy.19  
NON HLA GENES 
Case control studies  in Caucas ians  and Taiwanese populat ions  show an 
associat ion with cytochrome P-450 CYP 2D6 gene which is  involved in the 
met abolism of drugs. An associat ion has  also been seen with CARD15 and 
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int est inal inflammat ion. CARD15 binds  to bact erial cell wall components and 
is  a regulator of proinflammatory NFκB.5  
IL-I gene cluster is  an import ant  loci associated wit h susceptibility to 
spondy loart hropathy. 
ART S1 gene is  also associat ed with spondy loarthropat hy. T his  gene 
encodes  the endoplasmic ret iculum aminop eptidase, which cleaves  cytokine 
receptors  for IL-1 and TNFα from the cell surface and is  import ant  in antigen 
present at ion by class  I MHC molecules . 
The IL-23R gene which encodes  the receptor for IL-23 is  associat ed 
with spondy loarthropat hy. IL-23 promot es  survival of Th17 cells  which 
produces  IL-17, IL-6 and TNFα,  and recruits  inflammatory cells.  
Genes  poss ibly associated with spondyloart hropathy  includes  ANKH 
gene (involved in t ransport of inorganic pyrophosphate from intracellular to 
ext racellular compart ments) and HLA DRB1.19  
ROLE OF BACTERIA 
B27 transgenic rats  do not develop art hrit is if maint ained in a germ 
free environment . Exp osure of t hese rats  to bact eria, especially  bact eroides 
species , t riggers  the onset of both int est inal and joint inflammat ion. In 
humans , evidence of int est inal inflammat ion is present in upto 60% of 
spondy loart hropathy  pat ients . Elevat ed immunoglobulin IgA antibodies  to 
several bacteria have been observed, such as  Klebs iella p neumoniae and 
E.coli,  but  bacterial products  have not  been det ect ed in sacro iliac joint 
biopsies . Ant igen p resent ing cells  in int est inal mucosa and synovium t hat 
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express  t he CD163 scavenger receptor possess t he cap acity t o secrete TNFα 
and IL-1 in response t o bact erial lipopolysaccharide.5  
ROLE OF TNFΑ 
1) St imulat ion of endothelial cells  to exp ress  adhes ion molecules  
2) Recruit ment of leukocytes  into the inflamed synovium 
3) Induction of inflammat ory cytokine product ion like IL-1,IL-6 
4) St imulat ion of synovial cells  to release collagenases  
5) Induction of bone and cartilage resorpt ion 
6) St imulat ion of fibroblast proliferation. 
CD4+ T CELLS IN SPONDYLOARTHROPATHY 
On the bas is  of evidence from t he HLA-B27 t ransgenic animal models 
and the ident ification of an HLA-B27 homodimer structure which might 
mimic the structure of a MHC class II molecule, it  has  been hypothesiz ed t hat 
CD4+ T  cells ,  which convent ionally  recogniz e MHC class  II molecules, can 
recogniz e t he MHC class  I molecule HLA-B27, breaking the convent ional 
rules  of MHC rest rict ion. There are large numbers  of CD4+ T  cells  in 
diseased joints  which imp lies  t hat  CD4+ T  cells  p lays  a role in the 
pat hogenes is of spondyloart hropathy. 
Recognition o f empty HLA-B27  heterodimers  
One type of HLA-B27 reactive CD4+ T cell isolat ed, responded only to 
HLA-B27 expressed on the process ing defective cell lines  and did not  respond 
to HLA-B27 exp ressed on peripheral blood mononuclear cells  (PBMC) and 
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Ep stein Barr virus(EBV) transformed cell lines . Therefore it was unlikely t hat 
a convent ional form of HLA-B27 was  recogniz ed. Further st udies  imp lied t hat 
‘empty’ or ‘peptide-receptive’ HLA-B27 heterodimers  were recognized by 
these CD4+ T cells (i.e. ,het erodimers devoid of pept ide). MHC class I antigen 
process ing pathway defects occur in humans  by t he following ways.22  
1) Due t o genetic defects  in essent ial components  of the MHC class  I 
process ing pat hway – mutat ions  in the β2m gene and defects  in the 
express ion of TAP and LMP genes. 
2) During infection wit h intracellular p athogens  – alt erat ions  to t he MHC 
class  I process ing p athway  are most  commonly  observed during viral 
infect ion, eg: Cytomegalovirus and Herp es s implex infection. 
3) As a result  of t he act ion of cytokines  – t he ability of human IL-10 to 
efficiently  down-regulate the express ion of the LMP2 and TAP1 genes, 
which results  in inefficient  t ransport  of peptides  int o the ER, indicat es 
that  const itut ive or induced IL-10 production or alt ered cytokine 
patt erns  could lead t o deficiencies  in t he MHC class  I process ing 
pat hway.22 
Recognition o f an abnormally folded HLA-B27 complex  
A second type of HLA-B27 reactive CD4+ T  cells  recogniz e the 
ep itop e exp ressed on an abnormally  folded form of HLA-B27, poss ibly a 
homodimeric struct ure of HLA-B27. Whether t his  structure also presents  an 
ant igenic p eptide to the CD4+ T  cells  is  unknown. The fact t hat responses  are 
cons iderably enhanced by  the transfection of TAP suggests  that  there is  a 
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requirement for a TAP transport ed antigenic peptide. TAP dependent p eptides 
st abilize this  form of HLA-B27. 
Initial act ivat ion of t hese CD4+ T  cells  would p robably  require t raffic 
of ant igen present ing cells  bearing alt ered forms  of HLA-B27 (eg:infect ed 
dendritic cells) to regional ly mph nodes , but subsequent  recruitment of 
primed cells  to the joint  or to entheses  would result  in their act ivat ion if 
alt ered forms  of HLA-B27 were present locally. 
Act ivat ion of these CD4+ T  cells  would result  in the induct ion of an 
inflammatory response, with recruitment of inflammatory  cells,  such as 
macrophages  and other phagocytic cells,  t o entheses  or synovium, where they 
could be act ivat ed and release inflammatory cytokines. T he release of IL-8, 
TNFα and IL-12 at t his  s ite would act ivat e t he vascular endothelium, increase 
vascular p ermeability and activate ly mphocytes  and natural killer cells. 
Alt ernat ively, if t hese CD4+ T cells  provide help for B cells , t his  could result 
in the high levels  of IgA seen in SpA, p art icularly  if the T  cells  also secrete 
TGFβ.  Subsequent comp lement act ivat ion would result  in the lysis  of cells  by 
the membrane att ack complex, cytokine and p rost aglandin release and the 
recruit ment  of inflammat ory cells,  and likewise tis sue injury from products of 
act ivated leukocyt es. The pers ist ence of ant igen, in t his case unusual forms of 
HLA-B27, would result  in continued inflammat ion leading to t issue 
dest ruct ion.22  
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PATHOLOGY  
SACROILIAC JOINT  
This  is  an anat omically complex joint . T he anteroinferior portion 
(lower two third) is  a synovial joint.  T he post erosuperior p ort ion is 
ligamentous . T he cartilage overly ing t he sacrum is  thick and resembles 
hy aline cart ilage. It is  support ed by relat ively t hin bony  endplate. In contrast, 
the iliac cartilage resembles fibrocart ilage with more fibres  and less 
prot eoglycan. It is  supported by a thicker subchondral bony endp late. 
In early  st ages  of sacroiliitis,  t here is  cellular infiltrat ion with 
ly mphocyt es, macrophages  and plasma cells  in the synovium and subchondral 
marrow. Lat er features  include t he development  of pannus  ext ending from 
both synovium and subchondral bone marrow, with eros ions  of art icular 
cart ilage.  
Rep arat ive changes  include cartilage met aplas ia at  s it es  of act ive 
inflammat ion, followed by  its  calcificat ion and oss ification leading to bony 
ankylos is. Immunohistological st udies show t he presence of T ly mphocytes 
and macrophages  exp ress ing TNFα.  Transforming growth factor is  evident  at 
s it es of new bone formation.5  
SPINAL LESIONS  
   In most of the pat ients , t he disease progress t o involve the spine with 
a predilect ion for ap ophyseal joints, int ervert ebral discs , costovertebral and 
cost otransverse joints and extra-articular spinal ligaments.19  
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APOPHYSEAL JOINTS  
Early involvement  of the apophyseal joints  was  located at  t he bony 
attachment of the joint  capsule and was accompanied by increased fibroblasts, 
small vessels , lymphocytes, p lasma cells  and macrophages  which leads  to 
dest ruct ion of capsular insertion and adjacent  bone and forms  a p annus  t hat 
erodes  the margins of art icular cartilage.  
Advanced changes  include calcificat ion of art icular cart ilage, 
chondroid met aplas ia and oss ification of sub-synovium and fibrous  capsule 
usually  starting at  its  insert ion. Ult imately  joint  undergoes  central cartilage 
fus ion and peripheral ossificat ion leading to marginal ankylos is  forming a 
complet e t ube before the main part of the articular cart ilage is also dest roy ed. 
Once the joint  has  become immobile, the superficial layer of art icular 
cart ilage becomes  necrotic and replaced by oss ify ing connect ive t issue 
leading t o a bony plat e between t he remnants of cart ilage p lat es . 
Progress ion of disease is  typically  ascending so that  higher levels  of 
sp ine are progress ively affect ed although it  is not unusual to see advanced 
disease in the cervical apophyseal joints  wit h minimal changes  at  lower 
levels. Apophyseal joint  inflammation and ankylosis may also precede 
ankylos is  of adjacent  int ervert ebral disc sp ace. This  indicat es t hat the 
immobiliz ation caused by apophyseal joint  anky los is  may  be a factor in the 
development of vert ebral ankylos is. 
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Immunohist ological analysis  of apophyseal joints  has  shown 
subchondral infiltrat es  of CD4 and CD8 T  cells  and hypervascularisation and 
foci of CD68 ost eoclast ic cells.20  
INTERVER TEBRAL DISCS  
The most  common init ial feature is  t he appearance of granulation 
t issue either along t he whole outer annulus fibrosus  or at  its  att achment  to the 
bone anywhere on t he circumference. There are infilt rates  of lymphocyt es, 
plasma cells  and macrophages . Init ially there is  dest ruct ion of the ant erior 
s ide of t he normally  bulging vertebral rim which is  followed by bony 
proliferation in the adjacent trabecular bone and in the area of t he destroy ed 
annular fibres. The bony proliferat ion then grows  in the direct ion of the 
annulus fibrosus, perpendicular to the vert ebral axis .19  
ATLANTOAXIAL AREA  
The at lantoaxial region of t he upper cervical sp ine which is rich in 
fibrocart ilage, especially where the transverse ligament  attaches  to the arch of 
atlas  has  more predilection. Eros ion of t he insertion of t he transverse ligament 
int o the arch of at las, in combinat ion with destruct ion of the lat eral 
atlantoaxial joint  ult imat ely lead t o atlantoaxial dis locat ion and cord 
compress ion. Late findings  include ankylos is  of the joint  and osteoscleros is of 
the odontoid process  of t he axis .19 
COSTOVERTEBRAL AND COSTOTRANSVERSE JOINTS  
Inflammation in these joints  typically manifest  as  subchondral bone 
marrow edema. Hist opathological examination shows synovit is  and 
granulat ion t issue eroding the art icular cartilage as  pannus. Late feat ures 
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include chondroid met aplas ia, syndesmosis  and marginal ankylos is  leading to 
rest rict ion of chest  movement and decreased vit al capacity of lungs .19  
EXTRA-ARTICULAR SPINAL LIGAMENTS  
Marrow inflammat ion, bone eros ion followed by  ankylosis  typically 
involve t he intraspinal,  supraspinal ligaments  and ligamentum flavum. The 
ant erior and post erior longitudinal ligaments along the vert ebral bodies are 
usually not affect ed by oss ificat ion.19  
ENTHESIS  
ANATOMY AND PATHOLOGY  
The ent hes is  is  defined as  the s it e of insert ion of a tendon, ligament, 
joint capsule or fascia int o the periost eum of bone. T here are two major types : 
1) Fibrous  – pure dense fibrous  connect ive t issue that  links  the t endon or 
ligament  to bone. In long bones, fibrous  ent heses are locat ed at a 
cons iderable dist ance from a joint  and are thus  typical of tendons / 
ligaments  att ached to diaphyses. Eg : deltoid and pronat or teres. 
2) Fibrocartilaginous  – trans it ional zone of fibrocartilage at  the bony 
int erface.21 
These are charact erist ic of t endons and ligaments  attached t o ep iphyses 
and apophyses , where the direct ion of force transmitted by  the tendon / 
ligament  changes  throughout t he range of joint movement . Eg : Achilles 
t endon, tendon of supraspinatus . 
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F ibrocartilage is  a dynamic t issue t hat develops  at s it es  where entheses 
are subject ed to shear and compress ive forces . It  has  the ability t o promote 
bone format ion.21  
 Entheses  are well supplied with p ain and p ropriocept ive receptors. 
Recent  animal st udies have shown that  enthes is  itself is  aneural and that nerve 
fibres  are restrict ed to neighbouring t issues. Thus in its  lack of nerve fibers, 
ent hesis  fibrocartilage p arallels  t he art icular cart ilage of a synovial joint.  The 
fibrocart ilage is  also avascular and the blood supply is derived from vessels  in 
the perit enon, p erichondrium, periost eum and adjacent bone marrow. 
 Disease in spondy loarthtropathy  is  virt ually  restrict ed to 
fibrocart ilaginous  entheses . Four z ones  of t is sues  are recognised at 
attachment s it es. They are, 
1) Dense fibrous  connect ive tissue – parallel bundles  of collagen bundles 
separated by longitudinal rows of fibrocartilage. 
2) Uncalcified fibrocart ilage – fibrocart ilage cells  commonly arranged in 
longit udinal rows , replace the fibroblasts . These are associat ed with 
mat rix type II collagen fibers and prot eogly can. 
3) Calcified fibrocart ilage – less  cellular than its  uncalcified count erpart 
and having an extracellular matrix t hat  is heavily calcified. A st raight 
int erface called the ‘tidemark’ separates  calcified from uncalcified 
fibrocart ilage and is  the mechanical boundary  between hard and soft 
t issues.21 
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4) Bone – a bony cort ex at  a fibrocart ilaginous  enthes is  barely  exists ,  for 
even in a large tendon like the Achilles, t he subchondral bone plat e is 
generally little t hicker than one or two trabeculae. Indeed, the cort ex 
can be tot ally  absent . T herefore bone at the s it e of ent hesis is  closely 
int egrated wit h adjacent  trabecular bone. T here are complex 
int erdigit ations  of bone and calcified fibrocart ilage that  knit  t hem into 
each other, promoting the bas ic funct ion of t endon/ligament anchorage. 
There are no Sharpey’s fibers  where fibrocart ilage is  present  at 
ent heses, as t he subchondral bone plat e is  too t hin. Sharpey’s fibers are 
a p art icular feature of fibrous  entheses .21  
HISTOPATHOLOGY  
Chronic enthes it is  is  charact eriz ed by  bony  eros ions  and dest ruct ion, 
with inflammatory  infiltrates  evident  in t he bone adjacent  t o the ent hes is. 
Inflammatory  cells  including macrophages  and T  lymphocyt es  and edema in 
the bone marrow close t o fibrocartilage are observed. In lat er disease, 
capsular oss ification, my xoid bone marrow changes, chondroid met aplas ia, 
oss ification and format ion of synchondroses  are reported. T he only  direct 
evidence for TNF involvement  at  human entheses  comes  from st udies  in 
which TNF blockade leads  t o regress ion of enthes it is /osteit is  as  determined 
by  MRI. 
ENTHESITIS – BASED MODEL  
Small p art icles  (0.002-1.1 µm in diameter)such as  bact eria may 
localize to t rans it ional zones  such as  entheses, where richly  and p oorly 
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vascularised areas  are juxt raposed. Bacteria or t heir macromolecules 
contribut e to inflammat ion by unknown mechanisms. 
Biomechanical stress  occurs  at  entheses  in addit ion to other s it es  such 
as  aort a, lung apex, uvea in spondyloarthropat hy. This  suggests  t hat  stress  in 
the presence of microtrauma and subsequent  healing along with depos ition of 
bact erial products , may convert  a physiological healing response into an 
inflammatory response. Relevant feat ures  include t he sp ecial vascularity of 
ent heses, with subsequent act ivat ion of T oll-like receptors  by CpG mot ifs, 
lip opolysaccharide or bacterial heat shock prot eins. These may either direct ly 
or indirect ly  induce NFκB act ivat ion t hat  t riggers  an inflammatory  reaction 
with dendrit ic cell act ivat ion and T  cell co-stimulat ion leading to HLA-B27 
relat ed immune responses . Bact erial struct ural prot eins  and DNA alone, 
without  viable organisms  can init iate inflammatory  response at  ent heseal 
s it es.21  
CLINICAL FEATURES  
LOW BACK PAIN  
Inflammatory  type of low back ache is  a common presentat ion seen in 
90% of undifferentiat ed spondyloarthropat hy p atients. T he p ain is  initially 
felt  deep  in t he gluteal region, dull in charact er, difficult  t o localiz e and is 
insidious  in onset.  The buttock p ain typically alternat es  from s ide t o side. 
Buttock pain is  seen in 80% of undifferentiat ed spondyloart hropathy p atients.  
      Although t he pain is  oft en unilateral or int ermitt ent  at  first,  within 
a few months, it  usually  becomes  p ers ist ent and bilat eral.  The pain is 
associat ed wit h a feeling of low back st iffness  that  is  worse in the morning 
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and may  awaken t he p atient from s leep, part icularly in the second half of 
night . Morning stiffness may last upto 3 hours. Both the st iffness and low 
back ache t end to be eased by a hot shower bat h, an exercise program or 
phys ical act ivity; they do not  improve with rest.23  
BERLIN CRITERIA FOR INFLAMMATORY BACK ACHE IN 
PATIENTS WITH CHRONIC BACK ACHE ( >3 MONTHS )36  
1) Morning st iffness  > 30 minut es  
2) Improvement  with exercise but  not with rest  
3) Awakening at second half of the night because of back pain 
4) Alt ernat ing buttock pain 
The crit eria are fulfilled if at least  two out  of four paramet ers  are 
present . 
ENTHESITIS  
Ext ra articular pain at  certain s ites  is  a common complaint  in some 
pat ients . These les ions  are due t o enthes it is .  Common s it es  include sp inous 
processes , iliac crests, great er t rochanters , ischial tuberosit ies , tibial 
tubercles, cost osternal junct ions  and heels  (Achilles  enthes itis  or p lant ar 
fasciit is). Enthes it is is  seen in 85% of pat ients  with undifferentiat ed 
spondy loart hropathy  
CHEST PAIN  
    With subsequent involvement  of the t horacic sp ine (including 
cost overtebral and costotransverse joints ) and the occurrence of ent hesopat hy 
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at  the costost ernal and manubriosternal joints, p atient  may  exp erience chest 
pain accentuat ed by  coughing or sneezing, which is sometimes  charact eriz ed 
as  p leurit ic. M ild to moderate reduction of chest  exp ans ion is  oft en 
det ectable. Chest pain occurs relat ively oft en in HLA B27 pos it ive relatives, 
even in the absence of radiographic evidence of sacroiliit is.24  
ARTHRITIS  
Hips  and shoulders  (root  joints) are the most  frequent ly  involved extra 
axial joints . Peripheral art hrit is  is  seen in 35%. It affects  predominant ly the 
lower limbs  as  asymmetrical oligoarthritis .  Knee joints  are commonly 
involved. 
DACTYLITIS  
Dactylitis  is  swelling of an ent ire finger or t oe due t o synovit is  and 
t enosynovitis.  It is  seen in 17% of undifferent iat ed spondy loart hropathy. 
EXTRA ARTICULAR MANIFESTATIONS           
Ext ra art icular manifest at ions  are uncommon occurring in less  t han 
10% of pat ients  and include acut e ant erior uveit is ,  cardiac problems, oral 
ulcers, rash, non specific colitis  and ost eoporos is. Due t o restricted chest  wall 
movement, vital capacity  may  be moderately  reduced, whereas  res idual 
volume is  usually increased. 
UVEITIS 
Acut e anterior uveit is  is  t he most  common ext ra art icular 
manifest at ion. It  is  seen in 1-2% of undifferentiat ed spondyloart hropathy. 
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There is  no clear relat ionship between act ivity of the art icular disease and 
uveitis .5  
The onset of uveit is  is usually acut e and typically unilat eral but the 
attacks  may  alt ernate. The eye is  red and painful,  with visual impairment. 
Phot ophobia and increased lacrimat ion may  be present . If the eye remains 
untreat ed or if t reat ment  is  delayed, posterior synechiae and glaucoma may 
develop. Most att acks  subs ide in 4 -8 weeks  wit hout sequelae if early 
treat ment  is  provided. Acut e ant erior uveit is  is  more common in B27 pos it ive 
than B27 negative p atients.25  
CARDIAC MANIFESTATIONS 
Cardiac involvement  may  be clinically silent  or may  cause 
cons iderable problems. Manifest at ions of cardiac involvement include 
ascending aort it is,  aort ic valve incomp etence, conduct ion abnormalit ies, 
cardiomegaly  and p ericardit is.  In rare s ituat ions, aortit is  may  precede other 
features  of SpA. Aort ic incompet ence was  noted in 3.5% of pat ients  who had 
the disease for 15 years  and in 10% after 30 years.26 Inflammation and 
dilat ion of the aort a are the main causes  of aort ic valve incompet ence. 
Cardiac conduct ion dist urbances  are seen wit h increasing frequency 
with t he passage of time, occurring in 2.7% of those with disease of 15 y ears 
durat ion and in 8.5% after 30 years. Both aortic incompet ence and cardiac 
conduction defects  occur twice as  often in p atients  with peripheral joint 
involvement. 
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PHYSICAL FINDINGS 
LUMBAR SPINE 
On examinat ion of t he spine there may  be some limitat ion of 
movement  of the lumbar spine as  elicit ed by  forward flexion, hyperext ens ion 
or lateral flexion. Early loss  of the normal lumbar lordosis  is oft en t he first 
s ign and is eas ily assessed on inspect ion. 
SCHOBER’S TEST 
The Schober t est  is  used to det ect  limit at ion of forward flexion of the 
lumbar spine alt hough it  is  typically  normal in early disease. As  the pat ient 
st ands  erect, one mark is  placed on the skin overly ing t he fifth lumbar sp inous 
process  (usually  at t he level of the posterior sup erior iliac spine or the dimple 
of venus) and anot her mark is p laced 10 cm above in t he midline. The pat ient 
is  t hen asked t o bend forward maximally  without  bending the knees. If the 
distance between the both marks  does  not  reach 15 cm, t his  indicat es  reduced 
lumbar spine mobility.5  
In modified Schober’s  test,  one mark is  p laced at  t he level of fifth 
lumbar spinous  process . Second mark is  placed 10 cm above in the midline. 
Third mark is  p laced 5 cm below in t he midline. The p atient  is  then asked to 
bend and if t he dist ance between the second and t hird marks  doesn’t  reach 20 
cm, it  indicat es reduced lumbar spine mobility. 
Lat eral lumbar flexion- The p atient  bends  laterally  t o push t he middle 
finger down wit hout flexing forward or bending t he knees . The difference 
between t he st art  and end point  is recorded and the mean calculated; normal > 
10 cm. 
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CERVICAL SPINE 
1) Cervical rot at ion: t he mean of the right  and left cervical rot ation is 
recorded. Normal >70 degrees 27 
2) Occiput  to wall dist ance: pat ient  st ands , heels  and buttocks  against  the 
wall,  the head is  placed back as  far as  poss ible, keeping the chin 
horiz ant al.  Normal = 0 cm.27 
3) Tragus  to wall distance: pat ient  stands, heels and buttocks  against the 
wall,  the head is  placed back as  far as  poss ible, keeping the chin 
horiz ant al.  Normal <15 cm.27 
CHEST EXPANSION 
Chest  exp ansion should be measured on maximal inspiration aft er 
forced maximal exp irat ion at  the level of the 4th int ercost al space in males and 
just below the breast at  the xiphist ernal level in females. Normal values  are 
age and sex dep endent. Reduct ion below 5 cm in young p ersons is  abnormal.5  
SACROILIITIS 
1) Direct pressure over the sacroiliac joints may elicit p ain. 
2) Pelvic compression test: With the pat ient  in s ide ly ing pos it ion, 
downward pressure is  applied t o t he uppermost  iliac crest  direct ed 
towards  t he opposit e iliac crest . It  is intended to stret ch the post erior 
sacro iliac ligament. 
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3) Pelvic distraction t est : With t he pat ient  ly ing supine, a post erior and 
lat eral force is  applied to bot h ant erior sup erior iliac spine. It  is 
int ended to stret ch the anterior sacroiliac ligament. 
4) Patrick t est (FABER): This  t est st ret ches hip  and sacroiliac joint . The 
pat ient  is  asked to do flexion, abduct ion and ext ernal rot at ion of the 
hip. A pos itive test produces  back / butt ock pain whereas  groin p ain is 
indicat ive of hip pathology .28 
5) Gaens len’s  test: The p atient  should be p laced at  the edge of t he t able. 
Wit h t he p at ient  lying sup ine, the hip  is  maximally  flexed on one s ide 
and on t he oppos ite side, t he leg is  allowed to fall over the side of the 
s ide of the examination t able. This  stret ches  the sacroiliac joint and 
produces  pain. 
LABORATORY TESTS 
Generally  rout ine blood t ests  are not  helpful.  A normal ESR or normal 
CRP does  not  exclude act ive disease.5 An elevat ed ESR or CRP is  report ed in 
upto 36% of p atients, but  it may not  correlat e wit h clinical disease act ivity. 
Renal and liver function t ests  should be done before starting t he DMARDS 
therapy. 
HLA B27 
Typing for human leukocyte ant igen (HLA-B27) has  been suggest ed as 
a clinically  valuable diagnost ic t est  for anky los ing spondylitis,  Reit er’s 
syndrome, art hropathy  of inflammat ory  bowel disease and undifferentiat ed 
spondy loart hropathy. Diagnos is  can be made in most  pat ients  with diseases on 
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the bas is  of the history, physical examinat ion and radiologic findings. The 
B27 test  cannot  be used to screen an asy mptomat ic populat ion to detect  these 
diseases  and should not be thought of a routine diagnost ic t est.  
Over 90% of all p atients  with ankylos ing spondylit is  carry t he HLA-
B27 gene, which however is  only  present  in 8% of t he healt hy populat ion. 
HLA B27 pos itivity varies  in different  studies from 25- 80%.29  
It  can be helpful in t he diagnos is  of suspect ed cases of 
spondy loart hropathy. 
1) Pat ients wit h asy mmet ric oligoart hrit is in lower limbs and enthes it is  
2) Pat ients wit h inflammat ory back ache but no sacroiliitis on imaging. 
3) Anterior uveitis.  
HLA-B27 is  not a definit ive t est t hat can be used t o diagnose or rule 
out a disorder. 
HLA-B27 is  detect ed by microlymphocytotoxicity, flow cytometry and 
polymerase chain reaction. 
IMAGING STUDIES  
CONVENTIONAL RADIOGRAPHY  
X rays are not suitable for early diagnos is of spondyloart hropathy. 
Radiologically  sacroiliitis  can be present, but  it  should be either 
unilat eral/bilat eral grade I or unilat eral grade II.  
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GRADING OF RADIOGRAPHIC SACROILIITIS 
Grade 0 : normal  
Grade 1 :     susp icious  
Grade 2 :   minimal sacroiliit is - small localized areas  wit h eros ions  or 
scleros is, without alt erat ions in joint width. 
Grade 3 : moderat e sacroiliit is  – wit h one or more of : eros ions, 
scleros is, pseudowidening, narrowing or fibrous ankylos is  
Grade 4  :       bony anky los is . 
 
 
X-ray pelvis showing  bilateral  grade II sacroiliiti s. 
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X-RAY SPINE 
Sp inal lesions  without  sacroiliit is  are never observed, although 
zy goapophyseal joint  involvement  at  a cert ain level and squaring can be 
present  and be the first  manifest at ion of spinal involvement .30  
MRI  
MRI st udies  of the sacroiliac joints  and spine in spondyloarthropat hy 
pat ients  det ects t he early stages of sacroiliit is  and have been used as  an 
object ive out come measure for clinical trials .  
Act ive inflammatory changes  are seen best  by fat  sat urated T2 
weighted turbo spin-echo sequence or a short t au invers ion recovery (STIR) 
sequence which can det ect  even minor fluid collect ions  such as  bone marrow 
edema. Alt ernat ively administrat ion of a p aramagnet ic cont rast medium 
(gadolinium) det ects  increased p erfusion (osteit is) in a T1 weight ed sequence 
with fat  saturation. Act ive inflammatory  les ions  appear as  hyperint ense 
s ignals. Apart  from bone marrow edema, STIR/ post-gadolinium T1 sequence 
det ects capsulitis,  synovitis  and enthes itis.  
Chronic inflammat ory  les ions  are best  seen with T 1 weight ed 
sequence. It  helps  to det ect  scleros is, eros ions, fat  depos ition and bony 
bridges /anky los is . 
Sp inal inflammat ion can also be assessed by MRI. Romanus les ions 
app ear as hypointense signal on T 1 weight ed image, hyperint ense on post-
gadolinium T1 and STIR sequences . They  also helps  to det ect 
spondy lodiscit is . Contrast enhancement  was absent in cases  of syndesmophyte 
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format ion.  Syndesmophytes  are best  seen with T1 weight ed images . Post erior 
elements  such as  facet  joints , pedicles  and transverse p rocesses  can show 
inflammatory lesions. 
MRI is  very useful to assess  enthes it is  problems such as  Achilles 
ent hesit is  and plantar fasciit is .31  
CT  
CT  scan is  usually  cons idered sup erior to MRI  for diagnos ing  joint 
eros ions, subchondral scleros is  and bony anky los is . It  is  also useful to 
diagnose sp inal fractures. 
ULTRASOUND  
Ultrasound is  useful for imaging the p eripheral joints. It can det ect 
synovial effus ions , synovial thickening, t enosynovit is.  Ultrasound is 
relat ively inexp ens ive and does  not  convey radiation exp osure t hat is  inherent 
in convent ional radiography. 
Ultrasound helps t o diagnose enthes it is.  The ultrasound appearance of 
ent hesit is  is  that of hypoechoic thickening and edema, with eros ion, new bone 
format ion or changes  in entheseal vascularity  on power doppler  
ult rasonography.21  
The abnormal flow s igns  at  the sacroiliac joints  can be detect ed by 
power doppler ult rasonography. Low resistance index values and 
vascularisation of the sacroiliac joints provide evidence for act ive sacroiliit is. 
Doppler USG is  more sens it ive in det ecting sacroiliit is  than in det ecting 
ent hesit is .31  
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BONE SCINTIGRAPHY  
Bone scintigraphy  is  a useful adjunct  for evaluat ing sacroiliac joint 
disease. It  confirms  the presence of hyperemia and inflammat ion that may not 
be seen radiographically.31  
OUTCOME OF UNDIFFERENTIATED 
SPONDYLOARTHROPATHY 
In t he adult  populat ion a s ignificant  number of p atients  with 
undifferent iat ed spondyloarthrop athy  can progress  t o a definite 
spondy loart hropathy  (anky los ing spondy litis ,  psoriat ic art hrit is,  arthropat hy 
of IBD) aft er a variable length of follow up. Sany et  al.  found a definite SpA 
in 30% of 23 HLA B27 pos it ive uSpA pat ients  after 28 mont hs  of follow up. 
Schatt enkirchner and Kruger et  al.  with their study of 119 p atients  with HLA 
B27 pos it ive oligoart hrit is  during a follow up of 2-6 years, observed that  25% 
progressed t o a definit e SpA, 26% had recurrent  oligoarthritis  and 34% were 
asymptomatic. After a t en y ear follow up study, M au et  al.  observed a 
progression t o ankylos ing spondylit is  in 59% of 54 p atients  (from the original 
88 pat ients ) who comp leted t he st udy. In an Indian st udy by Kumar et al. 
analyzing t he 11 year follow up of 22 p at ients  with uSpA, 15 (68%) 
progressed to anky los ing spondylit is , one developed psoriatic arthritis,  two 
went  into natural remiss ion and four continued with uSpA. Samp aio Barros  et 
al.  found t hat  aft er a follow up  of t en y ears  wit h 111 pat ients , 27 (24.3%) 
pat ients  progressed to AS, 3 (2.7%) pat ients  to PsA while 25 (22.5%) pat ients 
went  into remiss ion.32,33 ,34    
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PROGNOSIS 
The following fact ors  are associated wit h a p oorer prognos is  in 
spondy loart hropathy.35  
1) Older age at onset  
2) Male sex 
3) Smoking 
4) Longer disease durat ion and great er severity 
5) Hip involvement 
6) Ext ra-axial involvement  (number of p eripheral joints  affect ed, ext ent 
of enthes it is) 
7) Ey e involvement  
8) Raised acut e phase reactants (ESR, CRP) 
9) Poor response to NSAIDS 
10) Presence of radiological changes at baseline 
11) Presence of HLA-B*4100, DRB1*0804, DQA1*0401, DQB1*0603, 
DRB1*0801 and DPB1*0202 alleles  
SpA in women may  not be as severe as  it is  in men and may present 
with isolat ed neck pain in the absence of typical back pain. Women t end to 
have less  severe involvement of the spine with peripheral joint involvement. 
SpA did not  adversely  affect  the ability  to conceive, p regnancy out come or 
neonat al health. 
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MATERIALS AND METHODS  
Place of study :  Department of Rheumatology , Rajiv Gandhi 
Government General Hosp ital & Madras Medical 
College, Chennai-3 
Type of study :  Prosp ect ive study. 
Durat ion of the st udy : 1 year (February 2011 to January 2012) 
Ethical Committ ee : Present dissert at ion was  approved by t he 
Inst itut ional Ethics Committee. 
Consent :  Informed written consent  was obt ained from all the 
pat ients .  
MATERIALS  
40 consecut ive undifferent iated spondyloart hropathy  pat ients  attending 
the Depart ment  of Rheumatology  outpat ient  clinics  and p atients  in 
Rheumatology wards  were included in t his st udy. 
INCLUSION CRITERIA  
Pat ients  who satisfy  Europ ean Spondy loarthropat hy St udy  Group 
Criteria. 
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EUROPEA N SPONDYLOARTHROPATHY STUDY GROUP 
(ESSG) CRITERIA 3  
Inflammatory  sp inal pain OR Synovit is  (asymmetric, predominantly  in 
lower limbs)  
and  
Any one of t he following  
Pos itive family history  
Psorias is  
Inflammatory bowel disease 
Alt ernat e buttock pain 
Ent hesopat hy  
Non gonococcalacut e uret hrit is,  cervicitis  or acut e diarrhoea 
within one mont h before arthrit is    
Sacroiliit is  
EXCLUSION CRITERIA   
Anky los ing Spondylit is (definite) 
Psoriat ic art hrit is  
React ive Arthiritis   
Arthropat hy of Inflammatory Bowel Disease 
Juvenile Ankylosing Spondy lit is   
Rheumatoid Arthrit is  
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 METHODS  
Each pat ient  underwent  det ailed hist ory regarding the age of onset of 
the disease, duration, low back ache, joint  pain and swelling, entheseal pain 
and red eyes . T hen patients were examined for involvement  of sacroiliac 
joints, peripheral arthritis ,  dactylit is,  enthes itis  and uveit is.  BASDAI, BASFI, 
BASMI and HAQ were done at  baseline and after one year. Laboratory 
paramet ers  included hemogram, RFT, LFT , RF, CRP, ASO and HLA B27. X 
ray p elvis was t aken at t he study ent ry and aft er one y ear. 
ANALYSIS  
To analyse t he clinical profile of undifferentiat ed spondyloarthropat hy 
- age of onset,  gender predispos ition, disease durat ion,presence or absence of 
sacroiliit is,  p attern of peripheral arthrit is ,  dactylit is,  enthes it is,  uveit is, 
elevation of acut e phase react ants  ESR/ CRP, HLA B27 pos it ivity, BASDAI, 
BASFI, BASMI, HAQ.  
To study the out come of undifferent iated spondyloarthropat hy aft er 
one year of follow up  – whether they  develop into ankylos ing spondy lit is  / 
psoriat ic arthrit is  / art hropathy  of inflammatory bowel disease or they 
continue to be undifferent iat ed spondyloarthrop athy. 
STATISTICAL ANALYSIS 
Mean and standard deviat ion were comput ed for cont inuous  data and 
proport ion was  calculated for discret e dat a. To compare t he mean values 
between the two groups  independent  t -t est  was  used. T he chi-square t est  was 
emp loy ed t o comp are t he p roportion between t he two groups . Analys is  was 
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two t ailed and p-value < 0.05 was  cons idered for st at istically  s ignificant. 
St at istical analys is was performed by us ing SPSS vers ion 16 package. 
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RESULTS 
  40 consecutive undifferent iat ed spondy loart hropathy  p atients  were 
examined clinically, investigated and followed up  for one y ear to assess  their 
out come. 
Sex  Distribution 
   Among t he 40 p at ients  of t he study, 36 (90%) were males  and 4 
(10%) were females. 
Sex Total No. (%) 
Male 36 (90%) 
Female  4(10%) 
90% 
10% 
SEX DISTRIBUTION 
male female
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Age 
The mean age of t he pat ients  was  30.2 years wit h t he range between 20 
and 47 years. 
Age at  onset o f disease 
Among the 40 pat ients , the mean age at onset  of t he disease was 28.4 
years wit h the range between 17 and 45 years. 
S EX Mean age at onse t Std. De vi ati on  
Male 28.03 7.894 
Female 32.00 6.683 
The p  value is  0.340  (stat ist ically  not  s ignificant  ).  T here is  no 
s ignificant  difference in  t he  mean age at  onset   of  the condition /disease 
between male and female. 
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Duration o f d isease 
The duration of the disease ranges  between 3 mont hs  and 6 y ears . The 
median duration of the disease was  15 mont hs. T he mean durat ion of the 
disease was 22.7 months . 
Duration of disease
52.5
47.5
45
46
47
48
49
50
51
52
53
< 2 YRS  ≥ 2YRS
P
er
ce
nt
ag
e
 
Duration Numbe r of Patients  Percentage  
< 2 YRS 21 52.5 
> 2YRS 19 47.5 
TOTAL 40 100 
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Back  ache 
Among the 40 p atients, 27 (67.5%) had inflammatory back ache, 10 
pat ients  (25%) had mechanical back ache and 3 pat ients  (7.5%) had no back 
ache at  the t ime of present ation.  
67.50% 
25% 
7.50% 
INFLAMMATORY
MECHANICAL
NIL
LOW BACK ACHE 
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Buttock  Pain 
Among the 40 p atients, 21 p atients  (52.5%) had buttock p ain and 19 
(47.5%) had no buttock pain.  
PRESENT 
52.50% 
ABSENT 
47.50% 
BUTTOCK PAIN 
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Peripheral  Arthriti s 
Among t he 40 pat ients , 38 (95%) had p eripheral art hrit is  and 2 (5%) 
had no evidence of peripheral arthrit is .  31 pat ients   (77.5%) had knee 
art hrit is,  29 (72.5%) had ankle arthrit is , 18 (45%) had foot  joints 
involvement, 8 (20%) had hand joints  involvement, 7 (17.5%) had hip  joint 
involvement, 5 (12.5%) had shoulder arthrit is  4 (10%) had wrist  arthrit is  and 
3 (7.5%) had elbow joint  involvement. 3 pat ients  (7.5%) had other joints 
involvement (acromioclavicular jt,  manubriost ernal jt, sternoclavicular jt  ) .  
Arthri tis  No.of Patients  % of Invol vement 
KNEE 31 77.50% 
ANKLE 29 72.50% 
FOOT JT S 18 45% 
HAND JT S 8 20% 
HIP 7 17.5% 
SHOULDER 5 12.5% 
WRIST  4 10% 
 ELBOW 3 7.5% 
OTHERS 3 7.5% 
77.50%
72.50%
45%
20% 17.50%
12.50% 10% 7.50% 7.50%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
K NEE ANK LE FOOT JTS HAND JTS HIP SHOULDE R WRIST  ELB OW OTHE RS
Peripheral Arthritis
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Sacro Iliac Joint  Arthriti s  
Among t he st udy  group, 25 pat ients  (62.5%) had S.I.  joint  involvement 
and 15 p atients  (37.5%) had no S.I.  joint  involvement  at  t he time of 
present at ion.  
62.50% 
37.50% 
S.I. JOINT ARTHRIS 
PRESENT ABSENT
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Enthesitis 
32 pat ients   (80%) had ent hesit is  and 18 (20%) had no enthes it is. 
Among them, 19 (47.5%) had p lant ar fasciitis ,  15 (37.5%) had Achilles 
t endon enthes it is,  4(10%) had ep icondyle ent hes itis  and 6 (15%)  p atients had 
pat ellar t endon enthes it is.   
47.50% 
37.50% 
15% 
10.00% 
20% 
PLANTAR
FASCIITIS
ACHILLES
ENTHESITIS
PATELLAR
TENDON
ENTHESITIS
EPICONDYLE
ENTHESITIS
Nil
ENTHESITIS 
 
Dactyliti s 
In our st udy, dactylit is  was  seen in 5 (12.5%) pat ients  and absent  in 35 
(87.5%) pat ients . 
Uveitis 
Among the 40 pat ients , uveit is was seen in 2 (5%) p atients.   
Family history 
Pos itive family  hist ory was  seen in only  one p atient (2.5%)  among the 
40 patients .  
   
 49 
HLA B27  
HLA B27 was posit ive in 23 (57.5%) pat ients  and negat ive in 17 
(42.5%) pat ients  
HLA B27
57.50%
42.50%
POSITIVE NEGATIVE
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ESR 
ESR was  elevated in 29 (72.5%) pat ients  and was  normal in 11 (27.5%) 
pat ients . T he mean ESR was 52.8.  
Mean 52.8 
Median  42.5 
Mode 40 
St d .deviat ion 37.07 
Range  125 
Minimum  5 
Maximum 130 
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ESR REMAINED AS uSpA PROG. TO AS/PsA 
Elevated  24 (82.8%) 5 (17.2%) 
Normal 9 (81.8%) 2 (18.2%) 
The p value is 1.0 whic h is not s ignif ic ant.  
CRP 
Among t he 40 pat ients, CRP was  pos itive in 27 (67.5%) p atients and 
negat ive in 13 (32.5%) p atients. 
CRP REMAINED AS uSpA PROG. TO AS/PsA 
Elevated  22 (81.5%) 5 (18.5%) 
Normal 11 (84.6%) 2 (15.4%) 
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X-RAY PELVIS 
X-ray  pelvis  was  t aken at  the t ime of p resentat ion and rep eated aft er 
one year. At  the t ime of presentat ion, 33 pat ients   (82.5%) had normal X-ray, 
3 (7.5%) had grade I changes and 4 (10%) had grade II changes . 
After 1 yr follow up, 23 pat ients  (57.5%) had normal X-ray, 8 (20%) 
had grade I changes, 7(17.5%) had grade II changes  and 2 (5%) had grade III 
changes . 
82.50% 
7.50%  10% 
0% 
57.50% 
20% 
17.50% 
5% 
NORMAL GRADE  I GRADE  II GRADE III
X‐RAY PELVIS 
X‐RAY AT STUDY  ENTRY X‐RAY  AFTER 1 YR
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DMARDS 
Among t he 40 pat ients , DMARDS t herapy was  start ed in 34 (85%)  
pat ients  and 6 (15%) were not on these drugs . Among t he p atients on 
DMARDS, 27 (67.5%) were on Methotrexat e alone, 3 (7.5%) were on 
Sulfasalaz ine alone, 4 (10%) were on both t hese drugs  and 1(2.5%) pat ient 
was  given Infliximab. 
67.50% 
7.50%  10.00%  2.50% 
15% 
MTX ONLY SSZ ONLY MTX + SSZ INFLIXIMAB NO DMARDS
DMARDS 
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BASDAI: 
The mean BASDAI at study entry was  6.2 and aft er one y ear was 3.1. 
BASFI 
The mean BASFI at st udy entry was  4.4 and aft er one y ear was 2.1. 
BASMI 
The mean BASMI at st udy entry was  3.5 and aft er one y ear was 2.3. 
HAQ 
The mean HAQ score at study entry was 1.36 and after one year was 0.7 
HEALTH INDICES AND HAQ
6.2
4.4
3.5
1.4
3.1
2.1 2.3
0.7
0
2
4
6
8
BASDAI BASFI BASMI HAQ
At Study Entry After 1 Year
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Correlation between HLA B27  and heal th indices 
INDICES 
(At study 
entry) 
HLA 
B27 
No. OF 
PATIENTS MEAN STD.DEV 
P 
VALUE 
Pos itive 23 6.55 .939 0.034 BASDAI 1 
Negat ive 17 5.80 1.223  
Pos itive 23 4.41 1.007 0.772 BASFI 1 
Negat ive 17 4.31 1.077  
Pos itive 23 3.54 .686 0.411 BASMI 1 
Negat ive 17 3.35 .755  
Pos itive 23 1.37 .124 0.720 HAQ 1 
Negat ive 17 1.35 .167  
The mean score value of BASDAI 1 is s ignificantly  ( p =0.034 ) higher 
in HLA B27 pos itive group  compare t o negat ive group.In the ot her health 
indices  there is  no s ignicant  difference in the mean score between pos it ive 
and negat ive group of HLA B27.  
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Outcome 
Of t he 40 pat ients , 33 (82.5%) pat ients  remained as  undifferentiat ed 
spondy loart hropathy, 5 (12.5%) pat ients  progressed to ankylos ing spondy lit is 
and 2 (5%) p atients progressed to psoriat ic arthritis after one year of follow 
up . 
100% 
0%  0% 
82.50% 
12.50%  5% 
uSpA AS PsA
OUTCOME 
AT STUDY ENTRY AFTER 1 YR
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Correlation between HLA B27  and outcome 
HLA B27 Outcome -uSpA Outcome  - AS + PsA 
Pos itive 16 7 
Negat ive 17 0 
This  is  st atistically s ignificant, p  value is  0.014. T his  shows t hat  there 
is  a s ignificant association between  HLA B27 and progress ion t o AS.   
Correlation between duration and outcome 
Duration Outcome  - uSpA Outcome  - AS+PsA 
<2 yrs  21 0 
> 2yrs  12 7 
This  is stat ist ically s ignificant , p value is  0.003.  This  indicat es  that the 
chance of progress ion to AS/ PsA is  s ignificant ly higher in p atients  with 
disease durat ion > 2 years. 
Hip involvement  and  progression to  ankylosing spondyliti s 
Hip Invol vement Outcome - AS Outcome – uSpA 
Present  4 3 
Absent  1 32 
This  is  st atistically s ignificant , p  value is  0.000957. This  t able shows 
that hip involvement  is associat ed with progression to AS. 
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DISCUSSION 
40 consecut ive pat ients  suffering from undifferentiat ed 
spondy loart hropathy  were taken up  for t he st udy  to assess  t heir clinical 
present at ion and t o st udy t heir out come aft er one year. 
Among the 40 pat ients , the mean age at onset  of t he disease was 28.4 
years  with the range between 17 and 45 years. This  is  in comparison wit h a 
Brazilian study  by  Sampaio Barros  et  al.,  (111 pat ients  followed up  for 10 
years),  where t he mean age at  onset  was  27.2 years34.  In an  Indian study  by 
Kumar et  al.  (22  p at ients  followed up  for 11 y rs),  the mean age at  onset  was 
17 y ears  wit h the range between 8 to 39 years.33 T he correlation between the 
mean age of onset and t he sex was  not s ignificant . 
In this  st udy, 36 (90%) were males  and 4 (10%) were females  which 
was  in s imilar wit h another Indian study by  Kumar et al.,  where 19 (86.4%) 
were males  and 3(13.6%) were females.33 In t he Braz ilian st udy by Sampaio 
Barros et  al.,  there were 90 (81.1%) men and 21 (18.9%) were women.34  
In t his  study, the duration of t he disease ranges  between 3 months  and 
6 y ears  and the mean duration of t he disease was  22.7 months  unlike the 
Indian study  by Kumar et al. ,  where the mean durat ion of t he disease was  8 
months  wit h the range between 4 and 24 months .3321 pat ients  (52.5%)  had 
disease durat ion less  than 2 years and 19 pat ients  (47.5%) with durat ion more 
than or equal to 2 years. All the pat ients  who progressed t o anky los ing 
spondy lit is /psoriat ic arthritis  had a disease duration of two or more years  and 
this  is stat ist ically s ignificant  (p value 0.003).  
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Of t he 40 pat ients, 27 (67.5%) had inflammatory back ache, 10 pat ients 
(25%) had mechanical back ache and 3 pat ients  (7.5%) had no back ache at 
the time of presentat ion. In cont rast,  in Kumar et al. st udy, inflammatory back 
ache was present in 100% of t he pat ients 33 and in Samp aio Barros et  al. st udy, 
inflammatory back ache was present  in 28.8% pat ients.34  
In this  study, buttock pain was present in 21 p atients  (52.5%). In 
Kumar et  al.  st udy, butt ock p ain was  seen in 77% of t he pat ients . Sampaio 
Barros et  al. study showed a less prevalence of buttock p ain (8.1%) at the 
t ime of presentat ion.34  
Among t he 40 pat ients , 38 (95%) had p eripheral art hrit is  and 2 (5%) 
had no evidence of peripheral arthrit is .  The patt ern of peripheral joint 
involvement  is  as  follows  : knee joints  – 31 pat ients (77.5%), ankle joints  – 
29(72.5%), foot  joints  – 18 (45%), hand joints  – 8 (20%), hip joints  -  7 
(17.5%), shoulder joints - 5 (12.5%), wrist  joints - 4 (10%) and elbow joints  - 
3 (7.5%). 3 p atients  (7.5%) had other joints  involvement  (acromioclavicular 
jt,  manubriost ernal jt, sternoclavicular jt  ) . Kumar et  al.  study showed  64% of 
hip  involvement, 18% of shoulder involvement , 77% of ankle involvement, 
82% of knee involvement and 50% of hand and wrist joint involvement. 
33Sampaio Barros  et al. st udy  showed 28.8% of knee involvement, 35.1% of 
ankle involvement, 10.8% of hip involvement. Elbow, wrist  and shoulder 
joints were not involved at the time of present at ion in the Braz ilian study.34  
Hip involvement  was  noted init ially in 7 pat ients , of which, 4 
progressed t o ankylos ing spondylit is  and t his  is  stat ist ically  s ignificant  (p 
value 0.000957). 
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In our study, 32 p atients   (80%) had enthes it is .  Of t hese, 19 (47.5%) 
had plant ar fasciit is ,  15 (37.5%) had Achilles t endon ent hesit is ,  4(10%) had 
ep icondy le ent hes itis  and 6 (15%)  p atients  had p atellar t endon ent hes itis .  In 
Kumar et  al.  st udy, 10 (45%)  pat ients  had ent hesit is 33 and in Sampaio Barros 
et  al.  study, Achilles  t endon ent hesit is  was  seen in 10.8% of t he pat ients  and 
plantar fasciit is  was seen in 9% of them.34  
In this  study, dactylitis  was  seen in 5 (12.5%) pat ients  and uveit is  was 
seen in 2 (5%) pat ients . In Kumar et  al.  st udy, uveitis develop ed in 4 pat ients 
(18%).33  
Pos itive family history was  seen in only  one pat ient  (2.5%) in this 
st udy. In Kumar et  al.  study, p os itive family  history  was  seen in 2 pat ients 
(9.1%) 33and in  Sampaio Barros  et  al.  study, 13 pat ients  (11.7%)  had 
pos it ive family history.34  
HLA B27 was posit ive in 23 (57.5%) pat ients  and negat ive in 17 
(42.5%) p at ients  which is  in contrast  to Kumar et  al.  study, where HLA B27 
was  pos itive in 100% of t he pat ients .33 In Sampaio Barros  et  al.  study, HLA 
B27 was  pos itive in 61.3% p atients.34   HLA B27 is  pos itive in all p atients who 
progressed to anky los ing spondy lit is /psoriat ic art hrit is  and this  is  st at istically 
s ignificant  (p  value 0.014). HLA B27 posit ivity  is associat ed wit h increased 
disease activity as  evidenced by t he st at ist ical s ignificance between HLA B27 
and BASDAI at the study entry  (p value 0.034). T he correlation between HLA 
B27 and BASFI, BASMI,  HAQ at  the entry  of the study are not  st at istically 
s ignificant . 
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ESR was  elevated in 29 (72.5%) pat ients  and was  normal in 11 (27.5%) 
pat ients . The median ESR was  42.5 with t he range between 5 and 130. In the 
Kumar et al.  study, the median ESR was  42 with the range between 15 and 
50.33 Correlat ion between elevat ed ESR and the out come was  analysed and 
found that t his correlat ion is  not s ignificant . 
Among t he 40 pat ients, CRP was  pos itive in 27 (67.5%) p atients and 
negat ive in 13 (32.5%) pat ients. There was no correlat ion between CRP and 
out come of undifferentiat ed spondyloart hropathy in this  study. 
In this  study, sacroiliac joint  was  involved clinically in 25 pat ients 
(62.5%).  
X-ray  pelvis  was  t aken at  the t ime of p resentat ion and rep eated aft er 
one year. At  the t ime of presentat ion, 33 pat ients   (82.5%) had normal X-ray, 
3 (7.5%) had grade I changes and 4 (10%) had grade II changes . 
After 1 yr follow up, 23 pat ients  (57.5%) had normal X-ray, 8 (20%) 
had grade I changes, 7(17.5%) had grade II changes  and 2 (5%) had grade III 
changes . In Kumar et al.  study compris ing 22 pat ients , after 11 years of 
follow up, 7 pat ients  had normal X- ray, 1 pat ient  had B/L grade II 
sacroiliit is,  13 pat ients  had B/L grade III sacroiliitis  and 1 p at ient  had B/L 
grade IV sacroiliit is.33  
Of t he 40 p atients who were enrolled in this  st udy, 33 (82.5%) pat ients 
continued to remain as  undifferentiat ed spondy loart hropathy  at  the end of one 
year, while  5 (12.5%) pat ients  progressed to anky los ing spondylit is and 2 
(5%) pat ients  progressed to psoriatic art hrit is.  No Indian studies  are available 
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for comp arison of outcome of undifferent iated spondyloarthrop athy at  the end 
of one year. Samp aio Barros  et al.  followed 68 p atients for two y ears  and in 
his st udy  75%  pat ients  remained as  uSpA, 13%  undergone remiss ion, 10% 
progressed t o AS and 2% progressed t o PsA.32 In the Indian st udy  by Kumar 
et al.,  15 (68%) developed anky los ing spondylit is , one developed psoriatic 
art hrit is,  four remain undifferent iat ed, and two had natural remiss ion at  the 
end of 11 yrs.33 Sampaio Barros  et  al. found that aft er a follow up of ten y ears 
with 111 pat ients , 27 (24.3%) pat ients  progressed t o AS, 3 (2.7%) p at ients  to 
PsA while 25 (22.5%) pat ients  went  into remiss ion.34  
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CONCLUSION 
1) Males  preponderence was not ed in t his one year follow up st udy of 
undifferent iat ed spondy loart hropathy p atients. 
2) The mean age at onset of the disease was  28.4 y ears . 
3) Involvement  of t he joints of lower limb appendicular skeleton was 
not ed predominant ly in t his st udy. 
4) The chance of progress ion to anky los ing spondylit is /psoriat ic arthrit is 
is  direct ly proportional t o t he durat ion of the disease.  
5) Hip involvement at t he t ime of presentat ion may predict  their 
progression to ankylosing spondylit is .  
6) Significant  number of pat ients  had elevat ion of acute phase reactants, 
both ESR and CRP. 
7) HLA B27 pos it ive pat ients  are more prone for progress ion to 
ankylos ing spondy litis /psoriatic arthrit is .  
8) Most  of the p atients  enrolled as  undifferentiat ed spondyloarthropat hy 
at  the beginning of this  study, continued t o remain so at  the end of one 
year follow up. 
9) All p atients of undifferentiat ed spondy loart hropathy should be 
followed up for their progress ion to ankylos ing spondylitis  or psoriatic 
art hrit is or inflammatory bowel disease.  
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A STUDY ON CLINICAL PROFILE AND OUTCOME OF 
UNDIFFERENTIATED SPONDYLOARTHROPATHY 
Name:      Age:  Sex:  Dat e: 
Address : 
 
RCC No. 
H/o. Present  Illness: 
 
 
 
 
 
Past  History: 
 
 
 
Personal History: 
Treat ment Hist ory : 
Family History 
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General Examinati on 
Pallor:   Ict erus   Cy anos is  
Clubbing:   Ly mphadenop athy:  Pedal Edema 
Skin: 
Nails : 
PR:    BP: 
 
Syste mic Examination 
CVS:    RS: 
 
Abdomen   CNS 
 
Musculoskeletal System Examination: 
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INVESTIGATION 
Hae mogram 
Hb:    TC:    DC: 
P latelet :   ESR: 
 
Immunologi cal  
CRP:    ASO:    HLA B27: 
 
Bi o-Chemistry 
Sugar:    Urea:    Creatinine: 
Bilirubin:   AST :    ALT : 
ALP:    Tot al Prot eins:  Albumin: 
 
Radiography 
X-ray Pelvis  
 
 
BASDAI 
BASFI 
BASMI 
 
HAQ 
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BASMI 
 
     B ASMI (average of 5 scores ) 
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BASDAI 
 
BASDA I= (Su m o f qu estions  1 to  4  + mean o f questions  5  and  6)  divid ed by  5 . 
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BASFI 
 
B ASF I= Average of 10 score 
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INDIAN HAQ 
Wi thout any 
di ffi culty 
Wi th  some 
di ffi culty 
Wi th  much 
di ffi culty 
Unable 
to do 
Acti vity of daily 
li ving (ADL): Are 
you able  to: 0 1 2 3 
Dress yourself,  
including tying 
sari/salwar/ 
dhoti/pyjama and 
doing butt ons? 
    
Get in and out  of 
bed? 
    
Lift a full cup or 
glass to your mouth? 
    
Walk out doors  on 
flat ground? 
    
Wash and dry your 
ent ire body ? 
    
Squat in t he toilet or 
s it cross- legged on 
the floor? 
    
Bend down to pick 
up  clothing from the 
door 
    
Turn a t ap on and 
off? 
    
Get in and out  of 
aut orickshaw/manual 
rickshaw/car? 
    
Walk t hree 
kilomet rcs? 
    
Shop in a veget able 
market ? 
    
Climb a flight  of 
st airs? 
    
Disability Index = Sum of all scores  divided by 12 
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PATIENT CONSENT FORM 
 
Study Title: A study on Clini cal Profile and Outcome of Undifferentiate d 
Spondyloarthropathy 
 
Part icipant Name:       Dat e: 
Age:         RCC.No: 
Sex: 
 
The det ails of the study have been provided to me in writ ing and 
exp lained to me in my own language. 
I confirm t hat I have understood the above study and had the 
opport unity to ask questions. 
I underst and t hat my part icip ation in the study is  volunt ary and that  I 
am free t o withdraw at  any  t ime, wit hout  giving any  reason, without  the 
medical care t hat will normally be provided by t he hosp ital being affected. 
I agree not  to restrict  the use of any data or results  t hat arise from this 
st udy provided such a use is only for scient ific purpose(s).  
I  have been given an informat ion sheet  giving det ails  of t he study. I 
fully consent t o part icip ate in the above study. 
 
Signature of the parti ci pant 
MuhŒ¢á x¥òjš got« 
MuhŒ¢á jiy¥ò 
“KJbfY«ò mH‰á nehÆ‹ j‹ik F¿¤j MŒî”  
MuhŒ¢á Ãiya« : _£L, jir k‰W« ïiz¥ò¤âR  
nehŒfËaš Jiw,  
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id. 
g§F bgWtÇ‹ bga® : 
ghÈd« : 
g§FbgwgtÇ‹ v© : 
g§F bgWgt® ïjid ( )  F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu§fŸ vd¡F És¡f¥g£lJ. 
v‹Dila rªnjf§fis nf£fî«, mj‰fhd jFªj És¡f§fis bgwî« 
thŒ¥gË¡f¥g£lJ.  
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g§nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l  á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
ïªj MŒî r«gªjkhfnth,  ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g§FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis 
gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš 
ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid Koîfisí« 
k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® nk‰bfhŸS« MŒÉš 
ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g§F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ ïªj MŒit nk‰bfhŸS« kU¤Jt 
mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ clš 
ey«ghâ¡f¥g£lhnyh mšyJ vâ®ghuhj  tH¡fâ‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clnd mij kU¤J mÂÆl« bjÇÉ¥ng‹ vd cWâ 
mË¡»nw‹. 
ïªj MŒÉš vd¡F ïu¤j«, áWÚ®,  v¡Þnu,  Þnf‹ k‰W« jir 
gÇnrhjid brŒJbfhŸs eh‹ KG kdJl‹ r«kâ¡»nw‹. 
 
g§nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g§nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
S. No NAME AGE AT ONSET (in 
years)
AGE  SEX RCC NO DURATION (in 
months)
LOW BACK ACHE BUTTOCK PAIN PERIPHERAL ARTHRITIS AT STUDY ENTRTY
1 Shankar 35 35 male 54535 3 mechanical  + Rt.shoulder,Lt.ankle,midtarsal jt
2 Rahuman 32 36 male 53281 48 inflammatory  + ‐
3 Santhana kumar 34 34 male 53600 6 inflammatory  ‐ Rt.wrist,Lt.hip,Lt.knee,Rt.ankle,Rt.midtarsal/subtalar jts
4 Vijayasarathy 26 30 male 51603 48 inflammatory  + Rt. shoulder,Rt. hip,B/L knee jts
5 Saravanan 27 30 male 53639 30 mechanical  + B/L ankle,midtarsal and subtalar jts
6 Arul kumar 24 28 male 48155 48 inflammatory  ‐ Rt hip,Lt knee jt
7 Devaraj 29 31 male 53951 24 inflammatory  +  ‐
8 Ibrahim 30 32 male 54091 24 inflammatory  + B/L knee,ankle jts
9 Manikandan 21 21 male 53293 6 inflammatory  ‐ Rt.3rd PIP/DIP jt,Lt.4th PIP/DIP jts,B/L acromioclavicular 
jts,Lt.ankle jt
10 Simon 24 24 male 54200 5 inflammatory  ‐ Lt.knee/ankle/midtarsal jts
11 Durai 20 23 male 50361 36 inflammatory  ‐ Lt.elbow,B/L knee,ankle,Rt.midtarsal/subtalar jts
12 Damodharan 29 35 male 51856 72 inflammatory  + B/L IP jt thumb,Lt.2nd PIP/DIP jts,B/L knee jts
13 Sundararajan 40 45 male 53782 60 mechanical  ‐ Rt.knee,Lt.ankle jts
14 Subramani 25 25 male 53223 6 inflammatory  + Lt.knee,B/L ankle,Rt.subtalar jts
15 Vetriselvan 20 20 male 53594 10 mechanical  ‐ Lt.wrist/3rd PIP/DIP jts,B/L knee/ankle/midtarsal/MTP jts
16 Haribabu 23 23 male 53746 3 ‐  + B/L knee/ankle jts
17 Kumaran 43 45 male 53947 15 inflammatory  ‐ Lt.knee/ankle jts
18 Narayanasamy 20 20 male 53622 6 inflammatory  ‐ B/L elbow/knee/midtarsal jts
19 Varadaraj 42 47 male 53589 60 mechanical  + Rt.hip,Lt.ankle/midtarsal jts
20 Ilavarasan 21 21 male 53990 4 inflammatory  + Rt.ankle/midtarsal/subtalar jts
21 JafferAli 17 21 male 54133 48 inflammatory  + Rt.hip,Lt.knee/ankle/4th MTP jt
22 Mahalingam 39 39 male 53327 9 inflammatory  + Rt.hip/wrist,Lt.midtarsal/subtalar jts
23 Arumugam 24 25 male 53436 12 inflammatory  + B/L knee,Rt.3rd PIP/DIP jts,manubriosternal jt
24 Mahendran 23 26 male 50041 36 inflammatory  ‐ Lt.sternoclavicular jt,Rt.wrist,B/L knee/ankle jts
25 Paapukumar 23 24 male 53091 12 inflammatory  ‐ B/L knee/midtarsal jts
26 Rajendran 27 30 male 53633 36 mechanical  ‐ Rt.knee,Lt.ankle jts
27 Venkatesan 19 22 male 51808 36 ‐  ‐ B/L knee/ankle jts
28 Selvakumar 19 21 male 51933 15 mechanical  ‐ Rt.shoulder/3rd PIP jt,Lt.knee,Rt.5th MTP/PIP jts,Rt.SC jt.
29 Kamaraj 20 20 male 53049 6 inflammatory  + B/L knee/ankle jts
30 Hari 27 27 male 53360 3  ‐  + B/L knee/ankle/subtalar/midtarsal/2nd,3rd MTP jts
31 Radha 26 26 female 54192 3 inflammatory  + B/L ankle/midtarsal jts
32 Ezhilarasi 33 35 female 53369 24 mechanical  + Lt.knee,B/L ankle jts
33 Kanagamani 41 43 female 54304 24 inflammatory  ‐ B/L knee/ankle jts
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
S. No NAME AGE AT ONSET (in 
years)
AGE  SEX RCC NO DURATION (in 
months)
LOW BACK ACHE BUTTOCK PAIN PERIPHERAL ARTHRITIS AT STUDY ENTRTY
34 Lakshmi 28 32 female 54374 48 mechanical  ‐ Lt.3rd PIP jt,B/L knee/ankle/midtarsal jts
35 Sahayaraj 45 45 male 54121 7 inflammatory   + Lt.knee,B/L ankle jts
36 Nageswar Rao 25 25 male 53260 9 inflammatory  ‐ Lt.knee,3rd MCP/PIP/DIP jts
37 Kumar 30 32 male 51962 15 inflammatory  ‐ B/L shoulder/elbow/knee/ankle jts
38 Tamilmani 26 28 male 52106 24 inflammatory  + Rt.shoulder/1,2,3,4 PIP jts/knee,Lt.ankle jt
39 Ramesh 37 37 male 54376 3 mechanical  ‐ B/L knee/ankle/midtarsal jts
40 Selvamani 43 45 male 50074 24 inflammatory  + Lt.hip,B/L knee/ankle jts
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
S.I. JT SCHOBER TEST ENTHESITIS AT STUDY ENTRY UVEITIS DACTYLITIS FAMILY HISTORY HLA B27 ESR (mm/hr) CRP (mg/L) ASO (IU/L)
 ‐ 5 cm B/L achilles  ‐ ‐ ‐ ‐ 45 >6 ‐
 + 4 cm B/L achilles  ‐ ‐ ‐ ‐ 11 ‐ ‐
 + 3 cm Rt achilles,Rt plantar fasciitis  ‐  ‐ ‐  + 120 6 200
 + 3 cm B/L plantar fasciitis ‐ ‐ ‐ + 45 >6 200
  ‐ 3 cm  ‐ ‐ ‐ ‐ + 18 6 ‐
 + 2.5 cm Lt achilles,Rt medial epicondyle enthesitis RE‐ant.uveitis  ‐ ‐  + 14 >6  ‐
 + 3 cm B/L plantar fasciitis, achilles enthesitis, Lt.patellar tendon
enthesitis
 ‐  ‐ ‐   + 11  ‐ 200
 ‐ 3 cm  ‐ ‐ ‐ ‐ + 10 6 ‐
 + 3 cm Lt.Achilles enthesitis  ‐ Lt.4th toe ‐  ‐ 71  ‐  ‐
 + 3 cm Lt.patellar tendon enthesitis,B/L plantar fasciitis ‐ ‐ ‐ + 30 >6 ‐
 ‐ 2.5 cm B/L medial epicondyle enthesitis,B/L Achilles enthesitis  ‐  ‐ ‐  + 100 >6   ‐
 + 1.5 cm B/L Achilles enthesitis,B/L plantar fasciitis ‐ Lt.2nd toe ‐ +  30 ‐ ‐
  ‐ 1.5 cm Lt.plantar fasciitis ‐ ‐ ‐ ‐ 20 ‐ ‐
 +  2 cm  ‐ ‐ ‐ ‐ + 130 >6 200
 + 2 cm Rt.lateral epicondyle enthesitis,Lt.plantar fasciitis  ‐ Lt.3rd finger ‐  + 85 6  ‐
 ‐  5 cm  ‐ ‐ ‐ ‐ ‐ 60 6 ‐
 ‐ 2 cm Lt.Achilles enthesitis ‐ ‐ ‐ + 40 ‐ ‐
 + 1.5 cm Rt.plantar fasciitis,Rt.patellar tendon enthesitis ‐  ‐ ‐ ‐ 100 6 200
 + 2 cm  ‐ ‐ ‐ ‐ ‐ 15 ‐ ‐
  + 2.5 cm Rt.plantar fasciitis, Rt.Achilles enthesitis ‐ ‐ ‐ + 60 ‐ ‐
 + 3 cm Lt.Achilles enthesitis RE‐old ant.uveitis,LE‐
ant.uveitis
 ‐ ‐  + 40 6  ‐
  ‐ 3 cm Lt.Achilles enthesitis ‐ ‐ ‐ + 88 >6 400
 + 3 cm  ‐ ‐ Rt.3rd toe ‐ + 26 >6 ‐
 ‐ 1.5 cm B/L plantar fasciitis ‐ ‐ ‐ ‐ 51 6 ‐
 ‐ 5 cm B/L plantar fasciitis ‐ ‐ ‐ ‐ 5 ‐ 200
 + 2 cm Lt.lateral epicondyle enthesitis,Lt.plantar fasciitis ‐ ‐ ‐ ‐ 15 ‐ ‐
 ‐ 4.5 cm B/L patellar tendon enthesitis ‐ ‐ ‐ ‐ 40 ‐ ‐
 + 2.5 cm B/L plantar fasciitis  ‐  ‐ ‐  + 87 >6  ‐
 ‐ 1.5 cm  ‐ ‐ ‐ ‐ + 62 6 ‐
 ‐ 3 cm Rt.Achilles enthesitis  ‐  ‐ ‐   ‐ 5 6  ‐
 + 2 cm B/L plantar fasciitis ‐ ‐ ‐ ‐ 112 6 200
 + 2 cm Lt.plantar fasciitis ‐ ‐ ‐ + 48 >6 ‐
 + 2.5 cm Lt.patellar tendon enthesitis ‐ ‐ ‐ + 38 ‐ ‐
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
S.I. JT SCHOBER TEST ENTHESITIS AT STUDY ENTRY UVEITIS DACTYLITIS FAMILY HISTORY HLA B27 ESR (mm/hr) CRP (mg/L) ASO (IU/L)
 + 1.5 cm Lt.Achilles enthesitis ‐ ‐ ‐ ‐ 25 ‐ ‐
 + 2.5 cm B/L plantar fasciitis ‐ ‐ ‐ ‐ 85 6 ‐
 + 1.5 cm Rt.plantar fasciitis ‐ Lt.3rd finger ‐ + 125 >6 ‐
 ‐ 2.5 cm Rt.plantar fasciitis ‐ ‐ ‐ ‐ 40 >6 ‐
 + 2 cm Lt.plantar fasciitis, Lt.Achilles enthesitis  ‐  ‐  +  + 110 >6  ‐
 ‐ 2.5 cm B/L patellar tendon enthesitis ‐ ‐ ‐ ‐ 20 >6 ‐
 + 2.5 cm  ‐ ‐ ‐ ‐  + 75 6 ‐
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
X RAY1 X RAY2 DMARDS BASDAI 1 BASDAI 2 BASFI 1 BASFI 2 BASMI 1 BASMI2 HAQ 1 HAQ 2 OUTCOME
normal normal  ‐ 2.6 1.6 2 1.3 3 2.6 1.16 0.58 uSpA
normal normal  ‐ 4.4 3.8 3.9 2 3.3 3 1.58 0.67 uSpA
normal Rt.grade I MTX 7.6 5 6.1 4.4 3.7 3.1 1.5 1.08 uSpA
Rt grade I B/L grade II MTX 6 7.9 1.9 2.8 3.4 4.2 1.42 1.58 AS
normal normal MTX 6.2 2.6 3.3 1 3.2 2.3 1.25 0.5 uSpA
Rt.grade II Rt grade III,Lt grade II MTX 4 4.2 3.7 3.8 2.6 2.5 1.33 1.16 AS
normal normal MTX 6.8 2 3.2 0.9 3.5 2.6 1.16 0.5 PsA
normal Rt grade I MTX 5 3.8 4.1 3.2 2.8 2.2 1.5 1 uSpA
normal Rt grade I SSZ 6.8 4.6 4.1 3.2 4.3 3.4 1.58 1.08 uSpA
normal normal MTX 7 3 4.7 1.9 3 2.3 1.5 0.58 uSpA
normal Lt grade II MTX,SSZ 6.1 3.8 4.3 1.4 3.8 2 1.58 0.5 uSpA
normal Lt grade I MTX 5.9 3 4.3 1.3 4.3 3 1.33 0.5 PsA
normal normal MTX 5.3 1.2 3.9 1.2 4.1 2.9 1.5 0.58 uSpA
normal normal MTX 7.6 5.6 5.4 3.3 4.1 2.8 1.33 0.91 uSpA
normal Rt grade I MTX 8.4 0.6 6.1 1.2 4.3 1.9 1.67 0.25 uSpA
normal normal MTX 5.4 1 4.9 0.8 2.1 1.8 1.5 0.33 uSpA
Lt grade II Lt grade II MTX 6.9 1 5.9 0.6 3.3 1.5 1.25 0.42 uSpA
normal normal MTX 7.6 1.4 5.1 0.8 3.8 1.7 1.58 0.33 uSpA
normal normal  ‐ 6.8 7 4.9 5.4 3.7 3.9 1.08 1.5 uSpA
Rt grade II Rt grade II MTX 6.7 7.2 5.1 5.2 3.6 3.7 1.33 1.58 uSpA
Rt grade I B/L grade II MTX 6.1 4.2 4 3.2 1.8 1.6 1.25 1 AS
normal normal SSZ 6.6 1.2 4.5 1.4 3.2 1.2 1.42 0.5 uSpA
normal Rt grade I SSZ 6.2 4.8 3.6 2.4 2.8 1.8 1.42 1.08 uSpA
normal normal MTX 7.2 3 6.6 2.3 4.2 2.1 1.42 0.42 uSpA
normal normal  ‐ 4.8 1 2.7 1 2.1 1.7 1.25 0.33 uSpA
normal normal  ‐ 6.6 4.4 4.4 2.9 3.3 2.1 1.25 0.83 uSpA
normal normal  ‐ 5.8 1.8 5 1.3 2.1 2 1.25 0.42 uSpA
normal normal MTX 6.4 4.3 4 2.8 3.5 2.7 1.33 0.91 uSpA
normal normal MTX 6.8 2.6 4.5 1.4 4.3 2.4 1.33 0.5 uSpA
normal Rt grade I MTX 5.2 1.6 3.9 1.5 2.5 1.7 1.16 0.33 uSpA
normal normal MTX,SSZ 7 4.1 5 3.4 3.8 2.7 1.42 1.08 uSpA
Lt grade I  Lt grade II MTX 7.6 4.3 5.2 3.7 3.6 2.8 1.25 0.91 uSpA
normal normal MTX 7 2.2 5 1.7 3.7 2.2 1.25 0.58 uSpA
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
X RAY1 X RAY2 DMARDS BASDAI 1 BASDAI 2 BASFI 1 BASFI 2 BASMI 1 BASMI2 HAQ 1 HAQ 2 OUTCOME
normal normal MTX 5.9 1.8 3.7 1.6 4.2 2.5 1.42 0.5 uSpA
normal Lt grade I MTX 5.4 1.8 5.6 1.5 3.5 1.7 1.16 0.33 uSpA
normal normal MTX 6.8 1.6 3.8 0.9 4.1 1.5 1.25 0.42 uSpA
normal normal MTX 5.4 2.6 3.8 1.3 3.7 2 1.25 0.42 uSpA
Lt grade II Lt grade III MTX,SSZ,Inflixim
ab
7.4 2.2 5 0.9 5 1.4 1.42 0.17 AS
normal normal MTX 6.4 1.4 3.8 1.3 3.3 1.8 1.42 0.5 uSpA
normal B/L grade II MTX,SSZ 5.6 4.1 3.7 2.6 3.9 2.6 1.42 1 AS
BASDAI‐1, BASFI‐1, BASMI‐1, HAQ‐1: At study Entry BASDAI‐2, BASFI‐2, BASMI‐2, HAQ‐2: After One Year
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